Evaluation of Adherence Rate in Patients Receiving PegIntron Pen [peginterferon alfa-2b] / Rebetol [ribavirin] for Hepatitis C
Phase of Trial: Phase III
Latest Information Update: 02 Jul 2015
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme; Schering-Plough
- 29 Jun 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 05 Jun 2009 Actual number of patients changed from 350 to 267 as reported by ClinicalTrials.gov.
- 21 Jul 2008 Status change